Please join your Goodwin team as we host SRS Acquiom for a breakfast event and panel discussion surrounding the launch of their newly released 2019 Life Sciences M&A Study on Life Sciences, which focuses on structured M&A activity.
SRS Acquiom’s recently released 2019 Life Sciences M&A Study gives a detailed look at deal terms and earnout achievement rates by year, sector and stage of development. The study draws from SRS Acquiom's experience as a professional shareholder representative on more than 100 structured life sciences deals involving almost 1,000 milestones potentially worth over $30 billion.
Click here to download a copy of the study.
Discussions will include:
- Key issues in negotiating these agreements
- Best practices for optimizing outcomes after the deal is announced
- An analysis of which milestones actually get paid, and when
Wednesday, October 2nd, 2019
8:30 am – 10:30 am
8:30 am – 9:00 am | Registration with Breakfast & Coffee
9:00 am – 9:10 am | Welcome Remarks – Michael Bison (Goodwin)
9:10 am – 9:40 am | Presentation of Data: Don Morrissey (SRS Acquiom)
9:40 am – 10:30 am | Panel Discussion
Goodwin's Boston Office
Conference Center | 100 Northern Avenue | Boston, MA
To RSVP, please click here.
Don Morrissey, Head of Life Sciences at SRS Acquiom
Todd Foley, Investor at MPM Capital
Kees Been, Founder, President & CEO of Lysosomal Therapeutics Inc. (LTI)
Ashish Contractor, Managing Director, Moelies & Company
Danielle Lauzon, Partner at Goodwin
Michael H. BisonPartner